AI-Powered Cervical Cell Analysis System Aids Early Cancer Detection

Noul Co., Ltd. (Yongin, South Korea) launched its miLab Cartridge CER, a specialized device for automatically staining and evaluating cervical cells. The cervical cell analysis product works on samples from cervico-vaginal smears, either manually prepared or using liquid-based cytology (LBC). It employs the Papanicolaou staining method, enhanced by Next Generation Staining and Immunostaining (NGSI), a proprietary staining technology developed by Noul. When paired with Noul's AI-driven diagnostic system, miLab, it provides staining, imaging, and cellular analysis results that aid in making diagnostic decisions.

The miLab Cartridge CER leverages cervical cytology for screening and is capable of identifying the detailed stages of cervical pre-cancer and cancer. This is achieved through AI-based morphological analysis, a key advantage offered by the miLab platform. Additionally, the product speeds up the total time for testing, making it easier for users to survey the entire sample area, differentiate between cells that are negative or positive for cancer, and focus on the cells most relevant for diagnosis. Noul received the CE mark for the miLab Cartridge CER in August 2022 and the CE-IVDR certification for the miLab platform in February 2023.

"Through the launch of cervical cell analysis products, we have made a real step forward in the cancer diagnostic business,” said David Lim, CEO of Noul. “The miLab Cartridge CER is compatible with both PAP smear and LBC methods, and it enables efficient and accurate cervical cell review with the full automatic staining and analysis. We want to contribute to the early diagnosis of cervical cancer, the fourth largest cancer in the world for women."

Related Links:
Noul Co., Ltd.